Predicting chronic responses to calcium channel blockade with a virtual population of African Americans with hypertensive chronic kidney disease.

ABSTRACT: Chronic kidney disease (CKD) is associated with the progressive loss of functional nephrons and hypertension (HTN). Clinical studies demonstrate calcium channel blocker (CCB) therapy mitigates the decline in renal function in humans with essential HTN. However, there are few long-term clinical studies that determine the impact of CCBs in patients with hypertensive CKD. African Americans (AA) have a higher prevalence of CKD and a faster progression to total kidney failure as compared to the white population but the mechanisms are poorly understood. Both clinical evidence (the African American Study of Kidney Disease and Hypertension, or AASK trial) and experimental studies have demonstrated that CCB may expose glomerular capillaries to high systemic pressures and exacerbate CKD progression.

SUBMITTER: Clemmer JS 

PROVIDER: S-EPMC11600446 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature